Exact Sciences has extended and made amendments to its agreement with Pfizer to promote Cologuard, the company announced recently.

“We’re thrilled to continue working with Pfizer to increase screening rates with Cologuard, especially during this critical time,” Exact Sciences CEO Kevin Conroy said in a statement. “Over the past two years, Pfizer has shown incredible commitment to Exact Sciences’ goal of eradicating colorectal cancer by helping detect the disease at its earliest, most treatable stages.”

According to a release, under the new terms, Pfizer will continue to provide marketing and related support for Cologuard and join Exact Sciences’ efforts to educate patients, physicians and health systems about Cologuard.

The collaboration will continue through the end of 2022.